P37.23 Real-World PD-L1 Expression in Lung Cancer and its Correlation with Driver Mutations
نویسندگان
چکیده
Expression of tumor programmed death ligand 1 (PD-L1) is associated with improved clinical benefit from immune-checkpoint inhibitors targeting the PD-1 pathway. PD-L1 expression assessed by proportion score (TPS) using immunohistochemistry (IHC) was approved to guide immunotherapy in advanced cancers. In this study, we performed data analysis real-world non-small cell lung cancer (NSCLC) and their correlation driver mutations identified a custom designed NGS panel. total, collected 598 Chinese NSCLC patients most them had stage IV All enrolled were IHC 22C3 pharmDx kit on Dako Autostainer Link 48 platform. Patients stratified into negative (TPS< 1%), positive (1%≤ TPS ≤49%) high (TPS≥50%) groups upon TPS. Among patients, 189 sequenced 500-gene panel identify somatic variants capture-based library preparation Illumina HiSeq X-Ten sequencing Overall, observed 51.5% 37.5% 11.0% cohort. them, prevalence rates 42.9% (45/105) vs. 53.5% (213/398), 41.0% (43/105) 36.9% (147/398) 16.2% (17/105) 9.5% (38/398) between squamous carcinoma adenocarcinoma, respectively. The (include expression) rate higher than adenocarcinoma. smokers non-smokers (55% 45%). We also found that EGFR mutant status (43.6% 61.1% for positive). Higher KRAS mutations, inversely correlated (L858R, 19del, G719X, Exon 20 ins, T790M, L861Q, S768I). wild type (16.0% 11.6%), significantly enriched group (26.3 12.4%). There are several studies showed associations cancer. Our results wild-type while contrary, which consistent previous reports. its patients. Such will give insights expression, inhibitor treatment.
منابع مشابه
PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC)
In order to explore the potential patient population who could benefit from anti PD-1/PD-L1 mono or combination therapies, this study aimed to profile a panel of immunotherapy related biomarkers (PD-1, PD-L1, CTLA-4 and CD8) and targeted therapy biomarkers (EGFR, KRAS, ALK, ROS1 and MET) in NSCLC.Tumor samples from 297 NSCLC patients, including 156 adenocarcinomas (AD) and 129 squamous cell car...
متن کاملTargeting PD-1/PD-L1 in lung cancer: current perspectives
Increased understanding of tumor immunology has led to the development of effective immunotherapy treatments. One of the most important advances in this field has been due to pharmacological design of antibodies against immune checkpoint inhibitors. Anti-PD-1/PD-L1 antibodies are currently in advanced phases of clinical development for several tumors, including lung cancer. Results from Phase I...
متن کاملAssociation between PD-L1 expression and driver gene status in non-small-cell lung cancer: a meta-analysis
Objective To assess the association between PD-L1 expression and driver gene mutations in patients with non-small-cell lung cancer (NSCLC). Method We performed a meta-analysis of 26 studies (7541 patients) which were published from 2015 to 2017. Pooled odds ratios (ORs) with 95% confidence intervals (CI) were calculated to describe the correlation. Subgroup analysis was performed based on pop...
متن کاملOver-Expression of Immunosuppressive Molecules, PD-L1 and PD-L2, in Ulcerative Colitis Patients
متن کامل
Correlation of MET gene amplification and TP53 mutation with PD-L1 expression in non-small cell lung cancer
Background The role of MET amplification in lung cancer, particularly in relation to checkpoint inhibition and EGFR WT, has not been fully explored. In this study, we correlated PD-L1 expression with MET amplification and EGFR, KRAS, or TP53 mutation in primary lung cancer. Methods In this retrospective study, tissue collected from 471 various tumors, including 397 lung cancers, was tested fo...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2021
ISSN: ['1556-0864', '1556-1380']
DOI: https://doi.org/10.1016/j.jtho.2021.01.770